Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toludesvenlafaxine vs Desvenlafaxine for Anhedonia in MDD
NCT06270433Recruiting
- Sponsor
- Affiliated Brain Hospital of Nanjing Medical University
- Start
- Feb 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of toludesvenlafaxine in major depressive disorder (MDD) (2 arms), sponsored by Affiliated Brain Hospital of Nanjing Medical University. Primary endpoint: Snaith-Hamilton Pleasure Scale Total Score at 8 weeks. Started Feb 2024; status: recruiting.
02
Drugs
toludesvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06270433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06270433.